SmithKline Beecham Corporation and Glaxo Group Limited (GSK)
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 8 disclosed transactions, SmithKline Beecham Corporation and Glaxo Group Limited (GSK) concentrates its licensing activity in Oncology, Other, and InfectiousDisease. SmithKline Beecham Corporation and Glaxo Group Limited (GSK) pays a 1.50x premium over market median. Their most common deal structure is Option, with an average disclosed value of $4.8B. Most recent activity: 2026.
Pipeline coverage & gaps
SmithKline Beecham Corporation and Glaxo Group Limited (GSK) has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| OptionPrimary | 4 | $257M | $6.0B |
| License | 3 | $40M | $1.2B |
| Acquisition | 1 | — | $10.6B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Nuvalent precision kinase inhibitor portfolio | Nuvalent | NSCLC / solid tumors | unknown | — | $10.6B |
| 2026 | HRS-9821 | Jiangsu Hengrui | COPD | unknown | $500M | $12.5B |
| 2025 | siRNA program | Frontier Biotechnologies | — | unknown | $40M | $963M |
| 2024 | mRNA-based immunology therapies | CureVac | immunology (undisclosed specifics) | unknown | — | $1.6B |
| 2024 | Up to 10 medicines and vaccines | Flagship Pioneering | — | discovery | $150M | $7.2B |
| 2024 | EGFR antibody-drug conjugate | Hansoh | oncology | phase_1 | — | $1.0B |
| 2023 | JNJ-3989 | Arrowhead/Janssen | hepatitis B | unknown | — | $1.0B |
| 2022 | RNA editing platform programs | Wave Life Sciences | neurology, metabolic and systemic indications | preclinical | $120M | $3.3B |
How this is computed
For each SmithKline Beecham Corporation and Glaxo Group Limited (GSK) deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 2.584, clamped to [0.7, 1.5].